Jilin Aodong reports strong profit growth despite revenue decline

Jilin Aodong Pharmaceutical Group reported a net profit attributable to shareholders of 1.28 bn yuan for the first half of 2025, a 138.44% increase year-on-year. This growth occurred despite a 20.21% decrease in operating revenue to 1.13 bn yuan. The company's total assets reached 34.15 bn yuan, up 3.48% from the end of the previous year, with net assets attributable to shareholders increasing by 3.21% to 29.96 bn yuan.

The improved performance was largely attributed to a 40.83% increase in investment income, mainly from its stake in GF Securities Co., Ltd., and a 126.15% rise in fair value changes from stock and fund holdings. The company maintains a "Medical Health + Financial Capital" dual-wheel drive strategy, leveraging financial assets to support its core pharmaceutical business.

In terms of profit distribution, the board of directors proposed a cash dividend of 2.00 yuan per 10 shares (including tax) for shareholders, based on 1,172,381,587 shares, after deducting 23,513,800 shares held in the stock buyback account. This distribution, along with a 120.01m yuan buyback, represents 100.00% of the distributable profit.